JonathanAlfredFletcherMD

Medical Genetics • Boston, MA

Clinical Cytogenetics

Associate Professor of Pathology, Brigham and Women's Hospital

Join to view full profile

Dr. Fletcher is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fletcher's full profile

Already have an account?

Office
75 Francis St
# Brigham
Boston, MA 02115
Phone+1 617-732-7883

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1986 - 1988
Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1985 - 1986
Boston University Medical CenterResidency, Internal Medicine, 1981 - 1985
Boston University School of MedicineClass of 1981

Certifications & Licensure

MA State Medical License 1985 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Medical Genetics and Genomics Clinical Cytogenetics

Publications & Presentations

PubMed

8 citations
E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor.
Alfonso García-Valverde, Jordi Rosell, Sergi Sayols, David Gómez-Peregrina, Daniel F Pilco-Janeta
Oncogene. 2021-10-07
27 citations
E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer.
Ke Li, Xufen Zheng, Hua Tang, Yuan-Sheng Zang, Chunling Zeng
The Journal of Experimental Medicine. 2021-08-02
11 citations
YWHAE-NUTM2 oncoprotein regulates proliferation and cyclin D1 via RAF/MAPK and Hippo pathways
Wen-Bin Ou, Meijun Z. Lundberg, Shuihao Zhu, Nacef Bahri, Anastasios Kyriazoglou
Oncogenesis. 2021-05-04

Journal Articles

LMTK3 Is Essential for Oncogenic KIT Expression in KIT-Mutant GIST and Melanoma
Jonathan A Fletcher, William H Fleming, Nature

Press Mentions

Demetri’s Team Approach Translates into Success in Sarcoma ResearchFebruary 10th, 2016

Grant Support

Core--Molecular CytogeneticsNational Cancer Institute2000–2002
Translocation Of 8-13 In Stem-Cell Leukemia/LymphomaNational Cancer Institute1997–1999
Tumor Suppressor Loci In MesotheliomaNational Cancer Institute1996–1998
Molecular Cytogenetics Of Solid TumorsNational Cancer Institute1990–1994